Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma

Endocrine-Related Cancer

Volumn 21, Issue 3, 2014, Pages 495-504

  Welander, Jenny ^a   Andreasson, Adam ^b   Brauckhoff, Michael ^c,d   Bäckdahl, Martin ^b   Larsson, Catharina ^b   Gimm, Oliver ^a,e   Söderkvist, Peter ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e Department of Molecular Medicine and Surgery Karolinska Institutet Karolinska University Hospital ^*  (Sweden)

Author keywords

Copy number; EPAS1; Gene expression; HIF2A; Mutation; Pheochromocytoma

Indexed keywords

DNA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; NUCLEAR FACTOR I; PROTEIN RET; RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EPAS1; TRANSCRIPTOME; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; TUMOR MARKER;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; DNA DETERMINATION; EXON; FEMALE; GENE DOSAGE; GENE EXPRESSION ASSAY; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; HYDROXYLATION; MALE; MICROARRAY ANALYSIS; MISSENSE MUTATION; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NON FAMILIAL PHEOCHROMOCYTOMA; PHEOCHROMOCYTOMA; PROTEIN DEGRADATION; PROTEIN STABILITY; SOMATIC MUTATION; ADRENAL TUMOR; CANCER STAGING; COHORT ANALYSIS; COPY NUMBER VARIATION; DNA MICROARRAY; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; PARAGANGLIOMA; PATHOLOGY; PROGNOSIS; SEQUENCE HOMOLOGY;

ADRENAL GLAND NEOPLASMS; ADULT; AMINO ACID SEQUENCE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; COHORT STUDIES; DNA COPY NUMBER VARIATIONS; EXONS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROGNOSIS; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR MARKERS, BIOLOGICAL;

EID: 84903584832     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0384     Document Type: Article

References (36)

1. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS & Sunyaev SR 2010 A method and server for predicting damaging missense mutations. Nature Methods 7 248-249.(doi:10.1038/nmeth0410-248)
2. Benjamini Y & Hochberg Y 1995 Controlling the false discovery rate-a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological) 57 289-300.
3. BentoC, PercyMJ,Gardie B,Maia TM, vanWijk R, Perrotta S,Della Ragione F, Almeida H, Rossi C, Girodon F et al. 2014 Genetic basis of congenital erythrocytosis: mutation update and online databases. Human Mutation 35 15-26. (doi:10.1002/humu.22448)
4. Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, ParfaitB,Bertherat J et al. 2011 Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics 20 3974-3985. (doi:10.1093/hmg/ddr324)
5. Burnichon N, Buffet A, Parfait B, Letouze E, Laurendeau I, Loriot C, Pasmant E, Abermil N, Valeyrie-Allanore L, Bertherat J et al. 2012 Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics 21 5397-5405. (doi:10.1093/hmg/dds374)
6. Castro-Vega LJ, Buffet A, De Cubas AA, Cascon A, Menara M, Khalifa E, Amar L, Azriel S, Bourdeau I, Chabre O et al. 2014 Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Human Molecular Genetics 23 2440-2446. (doi:10.1093/hmg/ddt639)
7. Chan DA, Sutphin PD, Yen SE & Giaccia AJ 2005 Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1a. Molecular and Cellular Biology 25 6415-6426. (doi:10.1128/MCB.25.15.6415-6426. 2005) (Pubitemid 41023218)
8. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, Leton R, Honrado E, Ramos-Medina R, Caronia D, Pita G et al. 2011 Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics 43 663-667. (doi:10.1038/ng.861)
9. Comino-Mendez I, deCubas AA, BernalC, Alvarez-EscolaC, Sanchez-MaloC, Ramirez-Tortosa CL, Pedrinaci S, Rapizzi E, Ercolino T, Bernini G et al. 2013 Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Human Molecular Genetics 22 2169-2176. (doi:10.1093/hmg/ddt069)
10. Dahia PL 2014 Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nature Reviews. Cancer 14 108-119. (doi:10.1038/nrc3648)
11. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS et al. 2005 A HIF1a regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genetics 1 72-80. (doi:10.1371/journal.pgen.0010008)
12. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, WaltherMM, LinehanWM, Munson PJ,Mannelli M, Goldstein DS & Elkahloun AG 2004 Distinct gene expression profiles in norepinephrine-and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocrine-Related Cancer 11 897-911. (doi:10.1677/erc.1.00838) (Pubitemid 40065561)
13. Favier J, Briere JJ, Burnichon N, Riviere J, Vescovo L, Benit P,Giscos-Douriez I, De Reynies A, Bertherat J, Badoual C et al. 2009 The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE 4 e7094. (doi:10.1371/journal.pone.0007094)
14. Favier J, Buffet A & Gimenez-Roqueplo AP 2012 HIF2A mutations in paraganglioma with polycythemia. New England Journal of Medicine 367 2161-2162. (doi:10.1056/NEJMc1211953)
15. Jochmanova I, Yang C, Zhuang Z & Pacak K 2013 Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. Journal of the National Cancer Institute 105 1270-1283. (doi:10.1093/jnci/ djt201)
16. Kaelin WG Jr & Ratcliffe PJ 2008 Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Molecular Cell 30 393-402. (doi:10.1016/j.molcel.2008.04.009) (Pubitemid 351681994)
17. Keith B, Johnson RS & Simon MC 2012 HIF1a and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nature Reviews. Cancer 12 9-22. (doi:10.1038/nrc3183)
18. Lack EE 2007 Pheochromocytoma. In AFIP Atlas of Tumor Pathology: Tumors of the Adrenal Glands and Extraadrenal Paraganglia, pp 274-276. Washington, DC: American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology (U.S.).
19. Ladroue C, Carcenac R, Leporrier M, Gad S, Le Hello C, Galateau-Salle F, Feunteun J, Pouyssegur J, Richard S & Gardie B 2008 PHD2 mutation and congenital erythrocytosis with paraganglioma. New England Journal of Medicine 359 2685-2692. (doi:10.1056/NEJMoa0806277)
20. Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z, Huynh T, Grossmann M, Pacak K & Prchal JT 2013 A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. Journal of Molecular Medicine 91 507-512. (doi:10.1007/s00109-012-0967-z)
21. Maher ER 2013 HIF2 and endocrine neoplasia: an evolving story. Endocrine-Related Cancer 20 C5-C7. (doi:10.1530/ERC-13-0146)
22. Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P, Guerrero S, Lin WM, Pham T, Modrusan Z et al. 2009 Oncogenic activating mutations are associated with local copy gain. Molecular Cancer Research 7 1244-1252. (doi:10.1158/1541-7786.MCR-08-0532)
23. Pacak K, Jochmanova I, Prodanov T, Yang C,MerinoMJ, Fojo T, Prchal JT, Tischler AS, Lechan RM & Zhuang Z 2013 New syndrome of paraganglioma and somatostatinoma associatedwithpolycythemia. Journal of Clinical Oncology 31 1690-1698. (doi:10.1200/JCO.2012.47.1912)
24. Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, McMullin MF & Lee FS 2008 A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. New England Journal of Medicine 358 162-168. (doi:10.1056/NEJMoa073123)
25. Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F et al. 2010 Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics 42 229-233. (doi:10.1038/ng.533)
26. Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL et al. 2008 The kinesin KIF1Bb acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes and Development 22 884-893. (doi:10.1101/gad.1648608) (Pubitemid 351482842)
27. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J et al. 2011 Fast scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Molecular Systems Biology 7 539. (doi:10.1038/msb.2011.75)
28. Taieb D, Yang C, Delenne B, Zhuang Z, Barlier A, Sebag F & Pacak K 2013 First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. Journal of Clinical Endocrinology and Metabolism 98 E908-E913. (doi:10.1210/jc.2013-1217)
29. Thompson LDR, YoungWF (Jr.), Kawashima A, Komminoth P& Tischler AS 2004 Malignant adrenal phaeochromocytoma. In World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs, pp 147-150. Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng. Lyon: IARC Press.
30. Toledo RA, Qin Y, Srikantan S,Morales NP, Li Q,Deng Y, KimSW, PereiraMA, Toledo SP, Su X et al. 2013 In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocrine-Related Cancer 20 349-359. (doi:10.1530/ERC-13-0101)
31. Welander J, Soderkvist P & Gimm O 2011 Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocrine-Related Cancer 18 R253-R276. (doi:10.1530/ERC-11-0170)
32. Welander J, Larsson C, Backdahl M, Hareni N, Sivler T, Brauckhoff M, Soderkvist P & Gimm O 2012 Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Human Molecular Genetics 21 5406-5416. (doi:10.1093/hmg/dds402)
33. Welander J, Garvin S, Bohnmark R, Isaksson L, Wiseman RW, Soderkvist P & Gimm O 2013 Germline SDHA mutation detected by next-generation sequencing in a young index patient with large paraganglioma. Journal of Clinical Endocrinology and Metabolism 98 E1379-E1380. (doi:10.1210/jc.2013-1963)
34. Welander J, Andreasson A, Juhlin CC,Wiseman RW, BackdahlM, Larsson C, Gimm O & Soderkvist P 2014 Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. Journal of Clinical Endocrinology and Metabolism (In Press). (doi:10.1210/jc.2013-4375)
35. Yang C, Sun MG, Matro J, Huynh TT, Rahimpour S, Prchal JT, Lechan R, Lonser R, Pacak K & Zhuang Z 2013 Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood 121 2563-2566. (doi:10.1182/blood-2012-10-460972)
36. Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT & Pacak K 2012 Somatic HIF2A gainof-function mutations in paraganglioma with polycythemia. New England Journal of Medicine 367 922-930. (doi:10.1056/NEJMoa1205119)